1. Matrix Metalloproteinases as Potential Biomarkers and Therapeutic Targets in Liver Diseases
    Eline Geervliet et al, 2020, Cells CrossRef
  2. RNAi Nanomaterials and Nanovehicles: Inorganic Nanoparticles for RNAi
    Joseph Hardie et al, 2018, Handbook of Nanomaterials for Cancer Theranostics CrossRef
  3. Innovative Nanotechnological Formulations to Reach the Hepatic Stellate Cell
    Klaas Poelstra, 2020, Current Tissue Microenvironment Reports CrossRef
  4. The apparent competitive action of ECM proteases and cross-linking enzymes during fibrosis: Applications to drug discovery
    Nikolaos A. Afratis et al, 2018, Advanced Drug Delivery Reviews CrossRef
  5. Innovative nonviral vectors for small-interfering RNA delivery and therapy
    Danielle C. Arruda et al, 2017, Nanostructures for Novel Therapy CrossRef
  6. Oral vitamin-A-coupled valsartan nanomedicine: High hepatic stellate cell receptors accessibility and prolonged enterohepatic residence
    Nesrine S. El-Mezayen et al, 2018, Journal of Controlled Release CrossRef
  7. Kaempferol attenuates liver fibrosis by inhibiting activin receptor–like kinase 5
    Taifu Xu et al, 2019, Journal of Cellular and Molecular Medicine CrossRef
  8. Hepatic stellate cells specific liposomes with the Toll‐like receptor 4 shRNA attenuates liver fibrosis
    Yuwei Zhang et al, 2021, Journal of Cellular and Molecular Medicine CrossRef
  9. siRNA- and miRNA-based therapeutics for liver fibrosis
    Zhen Zhao et al, 2019, Translational Research CrossRef
  10. When healing turns into killing – the pathophysiology of pancreatic and hepatic fibrosis
    Pawel E. Ferdek et al, 2022, The Journal of Physiology CrossRef
  11. Target delivery of small interfering RNAs with vitamin E-coupled nanoparticles for treating hepatitis C
    Liang Duan et al, 2016, Scientific Reports CrossRef
  12. Co‐encapsulation of lupulon and xanthohumol in lecithin‐based nanoliposomes developed by sonication method
    Neda Khatib et al, 2019, Journal of Food Processing and Preservation CrossRef
  13. Rosmarinic acid counteracts activation of hepatic stellate cells via inhibiting the ROS-dependent MMP-2 activity: Involvement of Nrf2 antioxidant system
    Changfang Lu et al, 2017, Toxicology and Applied Pharmacology CrossRef
  14. Efficient drug and gene delivery to liver fibrosis: rationale, recent advances, and perspectives
    Somayeh Mahdinloo et al, 2020, Acta Pharmaceutica Sinica B CrossRef
  15. Dose-Dependent Antifibrotic Effect of Chrysin on Regression of Liver Fibrosis: The Role in Extracellular Matrix Remodeling
    Cornel Balta et al, 2018, Dose-Response CrossRef
  16. Hepatic stellate cell-targeted imatinib nanomedicine versus conventional imatinib: A novel strategy with potent efficacy in experimental liver fibrosis
    Nesrine S. El-Mezayen et al, 2017, Journal of Controlled Release CrossRef
  17. In vitro inhibition of hepatic stellate cell activation by the autophagy-related lipid droplet protein ATG2A
    Yun Hong et al, 2018, Scientific Reports CrossRef
  18. New IMB16-4 Nanoparticles Improved Oral Bioavailability and Enhanced Anti-Hepatic Fibrosis on Rats
    Xia Niu et al, 2022, Pharmaceuticals CrossRef
  19. How successful has targeted RNA interference for hepatic fibrosis been?
    Mohube Betty Maepa et al, 2018, Expert Opinion on Biological Therapy CrossRef